Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Passes Above 50 Day Moving Average – Time to Sell?

Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.62 and traded as high as $0.7176. Galmed Pharmaceuticals shares last traded at $0.6775, with a volume of 115,859 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Galmed Pharmaceuticals has a consensus rating of “Sell”.

Galmed Pharmaceuticals Price Performance

The firm has a fifty day simple moving average of $0.62 and a 200 day simple moving average of $0.74. The company has a market capitalization of $4.13 million, a price-to-earnings ratio of -0.61 and a beta of 0.62.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 76.14% of the company’s stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.